10:51 AM EST - BriaCell Therapeutics Corp. : Is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT™, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract. BriaCell Therapeutics Corp.
shares T.BCT are trading down $0.52 at $6.74.
